Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
1607797-93-2
Molecular formula
C6468H10016N1724O2024S44
Molecular weight
~146000 g/mol
Drug class
Bispecific humanised monoclonal antibodydual VEGF-A and angiopoietin-2 (Ang-2) inhibitor
Mechanism of action
Binds VEGF-A and Ang-2, inhibiting VEGF-mediated neovascularisation and vascular permeability and reducing Ang-2-mediated vascular destabilisation and inflammation in the retina.
Indications / reported uses
Treatment of neovascular (wet) age-related macular degeneration (nAMD) in adults
Treatment of diabetic macular oedema (DME) in adults
Treatment of macular oedema following retinal vein occlusion (RVO) under product-specific authorisations
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Faricimab PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Faricimab Permitted Daily Exposure (PDE) report (the Faricimab PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Faricimab Occupational Exposure Limit (OEL) report (the Faricimab OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.